small molecule

VYKAT XR

DIAZOXIDE CHOLINE

Loss of exclusivityNovember 2035latest FDA-listed patent expiry
CompanySoleno TherapeuticsSee this company's full patent-cliff portfolio

Drug detail

Brand nameVYKAT XR
Active ingredientDIAZOXIDE CHOLINE
Strength150MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2025
Marketing statusRX

Listed patents

PatentExpiresType
12343348November 2035use U-4211
12178823November 2035use U-4167
9757384November 2035use U-4167
12419895November 2035use U-4275
7799777March 2029substance
7572789December 2026substance, product

Regulatory exclusivity

CodeExpires
ODE-532May 2032
ODE-532March 2032
NPMarch 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Not found